Hologic (HOLX) announced that its Aptima HPV Assay received FDA approval for clinician-collected HPV primary screening. Hologic’s human papillomavirus test is the only FDA-approved mRNA-based assay, designed specifically to detect infections most likely to lead to cervical cancer.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX: